BackgroundIt is unknown whether canagliflozin, a selective sodium glucose co-transporter 2 inhibitor, reduces epicardial adipose tissue (EAT) thickness, which is associated with insulin resistance and is a risk factor for coronary artery disease.Methods and resultsWe administered 100 mg of canagliflozin for 6 months to 13 patients with type 2 diabetes mellitus. We evaluated glycemic control, visceral adipose tissue (VAT) area and subcutaneous adipose tissue (SAT) area, and skeletal muscle mass by using impedance methods, and EAT thickness by using echocardiography. Canagliflozin treatment for 6 months decreased hemoglobin A1c level from 7.1 ± 0.5% to 6.7 ± 0.6% (P < 0.05) and decreased EAT thickness from 9.3 ± 2.5 to 7.3 ± 2.0 mm (P < 0.001), along with a trend of decreasing VAT and SAT area. No association was found between any of these changes.ConclusionCanagliflozin reduced EAT thickness in patients with type 2 diabetes mellitus independent of its effect on lowering blood glucose, suggesting that canagliflozin may have an effect in preventing cardiovascular events in these patients (UMIN000021327).
Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus
S. Yagi,Y. Hirata,T. Ise,K. Kusunose,H. Yamada,D. Fukuda,Hotimah Masdan Salim,Gulinu Maimaituxun,S. Nishio,Yuriko Takagawa,S. Hama,T. Matsuura,K. Yamaguchi,T. Tobiume,T. Soeki,T. Wakatsuki,K. Aihara,M. Akaike,M. Shimabukuro,M. Sata
Published 2017 in Diabetology & Metabolic Syndrome
ABSTRACT
PUBLICATION RECORD
- Publication year
2017
- Venue
Diabetology & Metabolic Syndrome
- Publication date
2017-10-04
- Fields of study
Medicine
- Identifiers
- External record
- Source metadata
Semantic Scholar, PubMed
CITATION MAP
EXTRACTION MAP
CLAIMS
- No claims are published for this paper.
CONCEPTS
- No concepts are published for this paper.
REFERENCES
Showing 1-35 of 35 references · Page 1 of 1